Orforglipron is the active substance in Foundayo, an oral tablet authorised in the United States. If you have been prescribed it, Veya records the days you take it and what follows, on one timeline. It records what you enter and nothing else, and it does not replace your prescriber's advice.

Orforglipron is the substance, Foundayo is the product

Most people meet this name through coverage of the trials rather than through a pharmacy. That coverage ran for years while the compound had no brand name, which is why the molecule name is the one that stuck and the one people search for.

What exists now is a tablet sold in the United States as Foundayo. This page covers what is worth recording about the substance. The product page carries the label detail, including how it is taken.

This page says nothing about what the trials found

Almost everything written about orforglipron is trial reporting, and a tracking app is not the place to summarise it. Veya makes no claim about what any medicine does, for this substance or any other, and a page that repeated trial results would be doing exactly that under a thin disguise.

What a tracker is good for is narrower and more useful: what you took, when you took it, and what you noticed afterwards, in a form you can hand to the person responsible for your treatment.

It is swallowed, which changes what a record is for

Orforglipron is taken as a tablet rather than injected. There is no site to note and no device to keep track of, so the record reduces to the day and whatever you observed, which is both easier to keep and easier to abandon.

The thing worth protecting is the run of consecutive days. One entry a day is enough, and a day marked as missed is worth more than a blank.

If your prescription names the substance rather than a brand

Prescriptions are sometimes written by active substance, and packaging does not always match what you expected to receive. Recording the name printed on what you actually have, rather than the name you have in your head, is what keeps a history accurate across a change of supply.

Questions about a particular product or supply belong with your prescriber or pharmacist rather than with a tracking app.

What Veya records for orforglipron

  • Daily tablet logOne entry a day. A run of days becomes something you can look at rather than something you have to reconstruct.
  • Symptom and side-effect notesWhat you noticed, the day it began and how long it lasted, sitting alongside the days you took your medicine.
  • Weight and measurement entriesRecorded when you choose to record them, at whatever interval suits you and your prescriber.
  • One record across a change of medicineEntries carry the medicine they relate to, so a move to or from another medicine leaves one continuous history.
  • Reminders you setA daily prompt on whatever schedule you choose. Veya reminds you to make an entry; it has no view on your treatment itself.
  • CSV exportYour entries out of the app as a CSV file, in normal use and after cancelling. It is your record, and it should read somewhere other than inside Veya.

What is worth writing down from the first day

Veya will not tell you what to take, and this page carries no schedule of amounts: that is between you and your prescriber, and it is on the information supplied with your medicine. What a record can do is make the early weeks legible later, when somebody asks how it has been going. These are the entries worth having.

  • The date you started, written down on the day.
  • The name printed on the product you actually received, rather than the one you expected.
  • A mark for each day you took it, including the days you did not.
  • Anything you noticed, with the date it started rather than a general impression of the week.
  • How long each symptom lasted, which usually tells a prescriber more than how bad it felt.
  • What you had eaten and drunk on a day a digestive symptom was notably worse.
  • Anything else that changed at the same time: a new medicine, an illness, travel, a different sleep pattern.
  • The questions you want to ask at your next appointment, written down when they occur to you.

What orforglipron is

Substance type
Orforglipron, a GLP-1 receptor agonist
Sold as
Foundayo, in the United States
Form
An oral tablet, swallowed whole, taken once daily
European authorisation
None. There is no European public assessment report for orforglipron or for Foundayo.

Read from the US prescribing information for Foundayo, sections 1, 2.1, 3 and 11, as published on DailyMed and retrieved on 11 September 2026. Prescribing information is reissued when it is updated. Always follow the information supplied with your own medicine, and speak to your prescriber or pharmacist about anything concerning your treatment.

Does Veya tell me what dose to take?

No, and it will not. Veya records what you enter. Decisions about your treatment belong to you and the prescriber who looks after it, and the information supplied with your medicine is the place to look for how it should be taken.

Is orforglipron the same as Foundayo?

Orforglipron is the active substance and Foundayo is the product that carries it in the United States. If you are holding a pack, the Foundayo page is where the label detail is.

Can I read about the trial results here?

No. Veya makes no claim about what any medicine does, and that includes repeating what a trial reported. Your prescriber and the information supplied with your medicine are the right sources for anything clinical.

Is it available in Europe?

There is no European authorisation for orforglipron. This page makes no comment on how anyone obtains medication, and Veya records what you enter regardless of where a prescription came from.

Is Veya connected to any manufacturer?

No. Veya is provider-neutral and independent. It does not sell, supply or prescribe medication, and it is not affiliated with any manufacturer.

Can I get my history out to show someone?

Yes. Entries export as a CSV file, which opens in a spreadsheet and prints. Handing over a printed sheet is often quicker than passing a phone across a desk.